Fibrinogen fractions in the third trimester of pregnancy and in puerperium

Thrombosis Research

Volumn 97, Issue 6, 2000, Pages 405-410

  Adler, Grazyna ^a   Duchinski, Tomasz ^a   Jasinska, Alicja ^a   Piotrowska, Urszula ^a  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

C reactive protein; Caesarean section; Fibrinogen; Fibrinogen fractions; Vaginal delivery

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN;

ADULT; ARTICLE; CESAREAN SECTION; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMOSTASIS; HORMONAL REGULATION; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PUERPERIUM; THIRD TRIMESTER PREGNANCY; VAGINAL DELIVERY;

ADULT; C-REACTIVE PROTEIN; CESAREAN SECTION; FEMALE; FIBRINOGEN; HUMANS; MOLECULAR WEIGHT; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY TRIMESTER, THIRD; TIME FACTORS;

EID: 0033993421     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00190-5     Document Type: Article

References (26)

1. Holm B., Nilsen D.W.T., Kierulf P., Godal H.C. Purification and characterization of 3 fibrinogens with different molecular weight obtained from normal human plasma. Thromb Res. 37:1985;165-176.
2. Handley D.A., Hughes T.E. Pharmacological approaches and strategies for therapeutic modulation of fibrinogen. Thromb Res. 87:1997;1-36.
3. Stirling Y., Woolf L., North W.R.S., Seghatchian M.J., Meade T.W. Hemostasis in normal pregnancy. Thromb Haemostasis. 52:1984;176-182.
4. Heilmann A., Hojnacki B., Spanuth E. Hämostase und Präeklampsie. [Haemostasis and Pre-Eclampsia] (in German with English abstract). Geburtsh u Frauenheilk. 51:1991;223-227.
5. Eguchi K., Mitsui Y., Yonezawa M., Oguni N., Hiramatsu Y. Changes of hemorheologic properties during normal pregnancy. Asia-Oceania J Obstet Gynaecol. 19:1993;109-114.
6. Hellgren M. Hemostasis during pregnancy and puerperium. Haemostasis. 26(Suppl. 4):1996;244-247.
7. Heinrich P.C., Castell J.V., Andus T. Interleukin-6 and the acute response. Biochem J. 265:1990;621-636.
8. Holm B., Godal H.C. Quantitation of three normally occurring plasma fibrinogens in health and during so-called "acute phase" by SDS electrophoresis of fibrin from EDTA-obtained plasma. Thromb Res. 35:1984;279-290.
9. Adler G., Eichman W., Targonska I., Szczepanski M. Increase of high molecular weight fibrinogen after surgery for renal cancer. Annals NY Acad Sci. 762:1995;388-390.
10. Gaffney P.J., Wong M.Y. Collaborative study of a proposed international standard for plasma fibrinogen measurement. Thromb Haemostas. 68:1992;428-432.
11. Watts D.H., Krohn M.A., Wener M.H., Eschenbach D.A. C-reactive protein in normal pregnancy. Obstet Gynecol. 77:1991;176-180.
12. Romem Y., Artal R. C-reactive protein in pregnancy and in the postpartum period. Obstet Gynecol. 151:1985;380-383.
13. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. New Engl J Med. 340:1999;448-454.
14. Regoeczi E., Hobbs K.R. Fibrinogen turnover in pregnancy. Scand J Haematol. 6:1969;175-178.
15. Muller-Berghaus G., Moeller R.M., Mahn I. Fibrinogen turnover in pregnant rabbits during the first and last thirds of gestation. Am J Obstet Gynaecol. 56:1978;233-241.
16. Ernst E. Oral contraceptives, fibrinogen and cardiovascular risk. Atherosclerosis. 93:1992;1-5.
17. Norris L.A., Bonnar J. The effect of oestrogen dose and progesterone type on haemostatic changes in women taking low dose oral contraceptives. Brit J Obstet Gynecol. 103:1996;261-267.
18. Meade T.W. Risks and mechanisms of cardiovascular events in users of oral contraceptives. Am J Obstet Gynecol. 158:1988;1646-1652.
19. Lee A.J., Love G.D.O., Smith W.C.S., Tunstall-Pedoe H. Plasma fibrinogen in women. Relationships with oral contraception, the menopause and hormone replacement therapy Brit J Haematol. 83:1993;616-621.
20. Meade T.W., Haines A.P., Imeson J.D., Stirling Y., Thompson S.G. Menopausal status and haemostatic variables. Lancet. 1:1983;22-24.
21. Stefanick M.L., Legault C., Tracy R.P., Howard G., Kessler C.M., Lucas D.L., Bush T.L. Distribution and correlates of plasma fibrinogen in middle-aged women. Arterioscler Thromb Vasc Biol. 15:1995;2085-2093.
22. Conard J., Mirabel C., Gompel A., Basdevant A., Pelissier C. Fibrinogen and plasminogen modification during oral estradiol replacement therapy. Fertil Steril. 68:1997;449-453.
23. Holm B., Nilsen D.W.T., Godal H.C. Evidence that low molecular weight fibrinogen (LMW) is formed in man by degradation of high molecular weight fibrinogen (HMW). Thromb Res. 41:1986;879-884.
24. Bilezikian S.B., Nossel H.L. Unique pattern of fibrinogen cleavage by human leukocytes proteases. Blood. 50:1977;21-28.
25. Bach-Gansmo E.T., Halvorsen E.T., Godal H.C., Skojønsberg O.H. Degradation of the α-chain of fibrin by human neutrophil elastase reduces the stimulating effect of fibrin on plasminogen activation. Thromb Res. 75:1994;307-317.
26. Adler G., Eichman W., Szczepanski M., Targonska I., Jasinska A. Postoperative plasma interleukin-6 in patients with renal cancer correlates with C-reactive protein but not with total fibrinogen or with high molecular weight fibrinogen fraction. Thromb Res. 89:1998;243-248.